" class="no-js "lang="en-US"> Sandoz - Medtech Alert
Tuesday, August 05, 2025
Sandoz | Pharmtech Focus

Sandoz

About Sandoz

Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Our products reach more than 500 million patients.

Related Story

Sandoz Biologics License Application for Proposed Biosimilar Denosumab Accepted by US FDA

February 6 2023

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US […]

Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA

July 26 2022

Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food […]